Johnson & Johnson announces new data from Phase 3 QUASAR study of tremfya

Johnson & Johnson announced new data from the tremfya Phase 3 QUASAR long-term extension study in adults with moderately-to-severely active ulcerative colitis. These data are among 24 abstracts highlighting the company’s research being presented at Digestive Disease Week 2025. Data from the QUASAR LTE study demonstrate patients treated with tremfya sustained clinical and endoscopic efficacy at Week 92: 72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92. 43% of patients were in endoscopic remission. Among patients achieving endoscopic improvement at Week 44, 84% maintained endoscopic improvement through Week 92. Patients treated with tremfya sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history. Safety data were consistent with the well-established safety profile of tremfya in inflammatory bowel disease with no new safety concerns identified.